As the first PD-1 inhibitor worldwide, nivolumab was reported with better clinical results than docetaxel in advanced NSCLC (median OS 9.2 vs. 6.0 months, response rate 20% vs. 9%, and median PFS 3.5 vs. 2.8 months in pretreated squamous NSCLC) (Pardoll, 2012). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.